切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2018, Vol. 06 ›› Issue (02) : 118 -123. doi: 10.3877/cma.j.issn.2095-5782.2018.02.006

所属专题： 文献；

专题研究·肿瘤介入

动脉化疗与静脉-动脉联合化疗治疗眼内晚期视网膜母细胞瘤的有效性与安全性
姜华1, 邓海浪1, 方倩2, 徐文婵1, 张靖1,†()   
  1. 1. 510120　广州市妇女儿童医疗中心介入&血管瘤科
    2. 510120　广州市妇女儿童医疗中心超声科
  • 收稿日期:2017-12-13 出版日期:2018-05-01
  • 通信作者: 张靖

Efficacy and safety of primary intra-arterial chemotherapy and intravenous plus intra-arterial chemotherapy for treatment of late-stage retinoblastoma

Hua Jiang1, Hailang Deng1, Qian Fang2, Wenchan Xu1, Jing Zhang1,†()   

  1. 1. Department of Interventional Radiology and Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou 510623, China
    2. Department of Ultrasound, Guangzhou Women and Children's Medical Center, Guangzhou 510623, China
  • Received:2017-12-13 Published:2018-05-01
  • Corresponding author: Jing Zhang
  • About author:
    Corresponding author: Zhang Jing, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

姜华, 邓海浪, 方倩, 徐文婵, 张靖. 动脉化疗与静脉-动脉联合化疗治疗眼内晚期视网膜母细胞瘤的有效性与安全性[J]. 中华介入放射学电子杂志, 2018, 06(02): 118-123.

Hua Jiang, Hailang Deng, Qian Fang, Wenchan Xu, Jing Zhang. Efficacy and safety of primary intra-arterial chemotherapy and intravenous plus intra-arterial chemotherapy for treatment of late-stage retinoblastoma[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(02): 118-123.

目的：

比较晚期视网膜母细胞瘤（RB）经眼动脉灌注化疗（IAC）与静脉化疗联合眼动脉灌注化疗（IV-IAC）的安全性与有效性。

方法：

选取2012年9月-2016年11月我院收治的眼内晚期(D/E期)初诊RB患者80例。42例进行经眼动脉灌注化疗，为IAC组；38例行2次静脉化疗后联合经眼动脉灌注化疗，为IV-IAC组；比较两组治疗方法的有效性与安全性。

结果：

（1）保眼与复发转移情况：IAC组42人46只眼球，平均随访20.2个月，39只眼成功保留，总体保眼率为84.7%。1例患者转移并死亡，转移率和死亡率为2.2%；IV-IAC组38人44只眼，平均随访21.4个月，34只眼成功保留，总体保眼率为77.3%，1例转移并死亡，转移率和死亡率为2.3%；两组复发率分别为13.0%（6/46）及15.9%（7/44）。两组保眼率、复发率、转移率、死亡率差异均无统计学意义（P>0.05）。（2）并发症：IAC组眼球内陷发生率为41.3%（19/46），4例患眼并发白内障，17只患眼眼睑水肿，12只眼睑下垂，1患眼斜视，1患眼玻璃体出血；IV-IAC组眼球内陷发生率为22.7%（10/44），15例眼睑水肿，12例眼睑下垂。IAC组眼球内陷发生率高于IV-IAC组（P=0.007）。

结论：

两次静脉化疗联合动脉化疗治疗晚期视网膜母细胞瘤对比单纯动脉化疗可能不会降低患者的总体转移率，但会降低患者眼球内陷和白内障的发生率。

关键词: 视网膜母细胞瘤, 经眼动脉灌注化疗, 静脉化疗, 保眼率, 并发症
Objective:

To compare the efficacy and safety of intra-arterial chemotherapy (IAC) and intravenous plus intra-arterial chemotherapy (IV-IAC) for patients with late-stage retinoblastoma.

Methods:

A total of 80 patients diagnosed with retinoblastoma between September 2013 and February 2016 without any treatment history were included. Forty-two patients treated with primary intra-arterial chemotherapy were defined as IAC group. Three-eight patients treated with primary twice intravenous plus intra-arterial chemotherapy were defined as IV-IAC group. Eye salvage rate, enucleation-free survival and mid-to-long term complications were assessed.

Results:

(1) Clinical results: A total of 46 eyes in group IAC were included. During the medium follow-up period of 20.2 months, the overall eye salvage rate was 84.7%, 1 patient was dead due to metastasis (2.2%) , 6 eyes developed recurrence (13.0%) ; Totally 49 eyes in group IV-IAC were included. Over all eye salvage rate was 77.3% with a medium follow-up period of 21.4 months. One patient died due to metastasis (2.3%) , 7 eyes developed recurrence (15.9%) . (2) Complications: Complications in group IAC were enophthalmos (n=19) , cataract (n=4) , vitreous haemorrhage (n=1) , orbital edema (n=17) and ptosis (n=12) . Complications in group IV-IAC were enophthalmos (n=10) , orbital edema (n=15) and ptosis (n=12) . The difference of the overall eye salvage rate, recurrence rate, metastatic rate and death rate between group IAC and group IV-IAC were not statistically significant (P>0.05) , but the enophthalmos rate was higher in group IAC (P=0.006) .

Conclusions:

The primary IV-IAC for retinoblastoma could not effectively lower the eye salvage rate, but it will reduce the incidence of enophthalmos and cataracts.

Key words: Retinoblastoma, Intra-artery chemotherapy, Intravenous chemotherapy, Eye salvage rate, Complication
图1 经眼动脉灌注化疗造影表现
表1 IAC组与IV-IAC组患儿的一般资料比较
组别 例数 发病年龄（月） 体质量(kg) 性别（男/女） 眼别 眼数（只） 分期
单眼 双眼 D期 E期
IAC组 42 15.7±1.2 10.6±1.3 28/14 38(90.5) 4(9.5) 46 37(80.4) 9(19.6)
IV-IAC组 38 16.1±0.9 11.2±1.8 24/14 32(84.2) 6(15.8) 44 33(75.0) 11(25.0)
统计量 ? t=0.41 t=0.72 χ2=0.48 χ2=1.54 ? χ2=0.22
P值 ? 0.825 0.415 0.582 0.208 ? 0.710
表2 IAC组与IV-IAC组患儿的并发症发生情况比较　只（%）
组别 眼数（只） 眼球内陷 白内障 玻璃体出血 眼睑水肿 眼睑下垂 斜视
IAC组 46 19(41.3) 4(8.7) 1(2.2) 17(37.0) 12(26.1) 1(2.2)
IV-IAC组 44 10(22.7) 0 0 15(34.1) 12(27.3) 0
χ2值 ? 5.75 - - 0.18 0.35 -
P值 ? 0.007 0.117Δ 1Δ 0.712 0.612 1Δ
[1]
Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma[J]. Nat Rev Dis Primers, 2015, 1:15021.
[2]
赵军阳.从从R-E到IRC分级:视网膜母细胞瘤治疗观念的转变[J].眼科，2007，16(6):368-372.
[3]
Shields CL, Kaliki S, Al-Dahmash S, et al. Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation[J]. Retina, 2013, 33(10):2103-2109.
[4]
Wilson MW, Qaddoumi I, Billups C, et al. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma [J]. Br J Ophthalmol, 2011, 95(4):553-558.
[5]
Kaliki S, Shields CL, Rojanaporn D, et al. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes[J]. Ophthalmology, 2013, 120(5):997-1003.
[6]
Chantada GL, Guitter MR, Fandiño AC, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve [J]. Pediatr Blood Cancer, 2009, 52(2):218-222.
[7]
Aerts I, Sastre-Garau X, Savignoni A, et al. Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation [J]. J Clin Oncol, 2013, 31(11):1458-63.
[8]
Gobin YP, Dunkel IJ, Marr BP, et al. Combined, sequential intravenous and intra-arterial chemotherapy（bridge chemotherapy）for young infants with retinoblastoma [J]. PLoS One, 2012, 7(9):e44322.
[9]
Choi S, Han JW, Kim H, et al. Combined chemotherapy and intra-arterial chemotherapy of retinoblastoma [J]. Korean J Pediatr, 2013, 56(6):254-259.
[10]
Yarovaya V, Sioufi K, Shields CL. Parafoveolar retinoblastoma regression with foveal preservation following intra-arterial chemotherapy documented on hand-held optical coherence tomography in a newborn [J]. Int J Retina Vitreous, 2017, 3:43.
[11]
中国抗癌协会肿瘤介入分会儿童肿瘤专家委员会.选择性眼动脉化疗术治疗视网膜母细胞瘤中国专家共识[J/CD].中华介入放射学电子杂志, 2016, 4(3):129-131.
[12]
Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma [J]. Arch Ophthalmol, 1996, 114(11):1330-1338.
[13]
Hahn SM, Kim HS, Kim DJ, et al, Favorable outcome of alternate systemic and intra-arterial chemotherapy for retinoblastoma[J]. Pediatr Hematol Oncol, 2016, 33(1):74-82.
[14]
Abramson DH, Daniels AB, Marr BP, et al. Intra-arterial chemotherapy（ophthalmic artery chemosurgery）for group D retinoblastoma [J]. PLoS One, 2016, 11(1):e0146582.
[15]
Chen M, Jiang H, Zhang J, et al. Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study[J]. Acta Ophthalmol, 2017, 95(6):613-618.
[16]
Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma[J]. Med Pediatr Oncol, 2003, 40(3):158-161.
[17]
Antoneli CB, Steinhorst F, de Cássia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience[J]. Cancer, 2003, 98(6):1292-1298.
[18]
Gündüz K, Müftüoglu O, Günalp I, et al. Metastatic retinoblastoma clinical features, treatment, and prognosis[J]. Ophthalmology, 2006, 113(9):1558-1566.
[19]
Leal-Leal CA, Rivera-Luna R, Flores-Rojo M, et al. Survival in extra-orbital metastatic retinoblastoma: treatment results[J]. Clin Transl Oncol, 2006, 8(1):39-44.
[20]
Youself YA, Soliman SE, Astudillo PP, et al. Intra-arterial chemotherapy for retinoblastoma: A systematic review[J]. JAMA Ophthalmol, 2016 Mar 17. doi: 10.1001/jamaophthalmol.2016.0244. [Epub ahead of print]
[21]
Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds[J]. Arch Ophthalmol, 2011, 129(11):1399-1406.
[22]
Tuncer S, Sencer S, Kebudi R, et al. Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: first 4-year experience from a single institution in Turkey[J]. Acta Ophthalmol, 2016, 94(7):e644-e651.
[23]
Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success[J]. Ophthalmology, 2006, 113(12):2276-2280.
[24]
Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes[J]. Ophthalmology, 2009, 116, 544-551.
[25]
Tse BC, Steinle JJ, Johnson D, et al. Superselective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings[J]. JAMA Ophthalmol, 2013, 131(7):903-911.
[26]
Friendly DS, Parks MM. Concurrence of hereditary congenital cataracts and hereditary retinoblastoma[J]. Arch Ophthalmol, 1970, 84(4):525-527.
[27]
Brown GC, Shields JA, Oglesby RB. Anterior polar cataracts associated with bilateral retinoblastoma[J]. Am J Ophthalmol, 1979, 87(3):276.
[28]
Ainsbury EA, Bouffler SD, Dörr W, et al. Radiation cataractogenesis: a review of recent studies[J]. Radiat Res, 2009, 172(1):1-9.
[29]
Vijayakrishnan R, Shields CL, Ramasubramanian A, et al. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? [J]. Arch Ophthalmol, 2010, 128(11):1427-1431.
[1] 金鑫, 谢卯, 刘芸, 杨操, 杨述华, 许伟华. 个性化股骨导向器辅助初次全髋关节置换的随机对照研究[J]. 中华关节外科杂志(电子版), 2023, 17(06): 780-787.
[2] 易晨, 张亚东, 董茜, 唐海阔, 刘志国. 应用骨盖技术拔除下颌低位骨性埋伏阻生第三磨牙的疗效观察[J]. 中华口腔医学研究杂志(电子版), 2023, 17(06): 424-429.
[3] 杜滨和, 徐楠, 杨云川, 崔培元. 5项改良衰弱指数预测胰十二指肠切除术近期预后的价值探讨[J]. 中华普通外科学文献(电子版), 2023, 17(06): 444-448.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 逄世江, 黄艳艳, 朱冠烈. 改良π形吻合在腹腔镜全胃切除消化道重建中的安全性和有效性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 66-69.
[6] 杨体飞, 杨传虎, 陆振如. 改良无充气经腋窝入路全腔镜下甲状腺手术对喉返神经功能的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 74-77.
[7] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[8] 陈大敏, 曹晓刚, 曹能琦. 肥胖对胃癌患者手术治疗效果的影响研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 651-653.
[9] 曹智, 朱希望, 王尉, 张辉, 杨成林, 张小明. 经皮肾镜碎石取石术中不同肾盂内压力与围术期并发症相关性研究[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(06): 616-620.
[10] 叶晋生, 路夷平, 梁燕凯, 于淼, 冀祯, 贺志坚, 张洪海, 王洁. 腹腔镜下应用生物补片修补直肠术后盆底缺损的疗效[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 688-691.
[11] 袁伟, 张修稳, 潘宏波, 章军, 王虎, 黄敏. 平片式与填充式腹股沟疝修补术的疗效比较[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 697-701.
[12] 夏松, 姚嗣会, 汪勇刚. 经腹腹膜前与疝环充填式疝修补术治疗腹股沟疝的对照研究[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 702-705.
[13] 潘冰, 吕少诚, 赵昕, 李立新, 郎韧, 贺强. 淋巴结清扫数目对远端胆管癌胰十二指肠切除手术疗效的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 608-612.
[14] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[15] 王小娜, 谭微, 李悦, 姜文艳. 预测性护理对结直肠癌根治术患者围手术期生活质量、情绪及并发症的影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 525-529.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号